Seminar – Feng-Chun Yang, M.D., Ph.D.

Event Date & Time

December 1, 2021 at 12 Noon

Location

Virtual Presentation


Event Details:

DEPARTMENT OF PHARMACOLOGY

SEMINAR SERIES

Wednesday, December 1, 2021

12:00pm – Virtual Presentation

Feng-Chun Yang, M.D., Ph.D.
Professor
Department of Cell Systems & Anatomy
The A.B. Alexander Distinguished Chair in Cancer Research, Mays Cancer Center
UT Health San Antonio
San Antonio, Texas

 

 

 

Save to Calendar

Add to Calendar

About the Speaker(s)

Dr. Yang’s laboratory has been focused on investigating the cellular/molecular mechanisms of hematopoietic malignancies, with a specific focus on mutations of ASXL1, ASXL2, PHF6 and NF1 in the pathogenesis of myeloid malignancies. Alteration of ASXL1 gene is frequent in multiple forms of myeloid malignancies, including myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), MDS/MPN (such as CMML and JMML), and acute myeloid leukemia (AML). In contrast, ASXL2 mutations are restricted to patients with t(8;21) AML patients both in children and adults at an incident of 23%. Interestingly, ASXL1 and ASXL2 mutations are mutually exclusive in t(8;21) AML. However, the role of ASXL1/ASXL2 in the pathogenesis of myeloid malignancies and in normal hematopoiesis remains largely unknown. Mutations in NF1 tumor suppressor gene cause the common genetic disorder neurofibromatosis type 1 (NF1) which is associated with a predisposition to JMML, MDS and AML. Our goal is to identify the therapeutic targets for the treatment of these gene mutation-mediated myeloid malignancies.